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Abstract 
Dihydroartemisinin-piperaquine phosphate (DHAPP) is an artemisinin based combined 
therapy and is very effective in treating malaria in areas of high resistance to conventional 
malaria. The present study investigates the toxicological effects of the use therapeutic dose 
of DHAPP in male and female rats. Thirty adult Wister rats of both sexes weighing between 
180 and 210 g were grouped into three consisting of 5 males and 5 females per group. The 
control group was orally administered with normal saline, the test and recovery groups were 
given body weight 15.4 mg/kg of DHAPP orally for three days after which the recovery 
group were allowed to recover from the drug’s effect for another three days. The blood 
samples were collected through cardiac puncture into heparinised tubes centrifuged at 
5000 rpm for 10 minutes. The kidney were also removed, weighed, blotted dry and 
homogenised. The supernatant of each of the plasma and kidney was kept in clean bottles, 
stored at -4oC and were used for kidney function and histological analysis.An increment 
was observed in the protein, creatinine and urea levels in the plasma while in the kidney, 
the levels decreased. In the plasma and kidney, all the biochemical parameters were 
observed to return to normal when the animals were left to recover. Sex related differences 
were noted in most of the groups in the plasma and kidney of the enzyme activities. 
Histological examination also revealed an intoxication of the kidney cell of the rats.It could 
therefore be inferred from these results that increases in protein, creatinine and urea levels 
in the blood plasma showed the possibility of abnormality in the renal system when the drug 
was administered. It is therefore recommended that the drug should be administered with 
caution. 
Keyword: Dihydroartemisinin-piperaquine phosphate (DHAPP); Artemisinin; Antimalarial; 
therapeutic dose. 
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1. Introduction 
Malaria is one of the most serious health challenges facing the world today. It is a mosquito-borne infectious disease of 
humans and other animals caused by Plasmodia and are also definitely the single most destructive and dangerous 
infectious agent in the developing countries of the world [1-3]. This disease results from the multiplication of 
Plasmodium parasites within red blood cells. Studies revealed that five species of Plasmodium can infect and be 
transmitted by humans [4]. 
There were an estimated 225 million cases of malaria worldwide in 2009 [5]. An estimated 655,000 people died from 
malaria in 2010, a decrease from the 781,000 who died in 2009, accounting for 2.23% of deaths worldwide [5]. However, 
a 2012 meta-study from the University of Washington and University of Queensland estimates that malaria deaths are 
significantly higher [6].   
Severe malaria disease is largely caused by Plasmodium falciparum while that caused by Plasmodium vivax, Plasmodium 
ovale and Plasmodium malariae is generally a milder that is rarely fatal [4]. Plasmodium knowlesiis a zoonosis that 
causes malaria in macaques which can also infect humans [7, 8].  
Currently, artemisinin-based combination therapy (ACT) is recommended for the treatment of P. falciparum malaria [5, 
9]. Fast acting artemisinin-based compounds are combined with a drug from a different class. Such drugs may include 
lumefantrine, mefloquine, amodiaquine, sulfadoxine, piperaquine and chlorproguanil [9].  
Malaria transmission can be reduced by preventing mosquito bites, use of mosquito nets and repellents, or by mosquito 
control measures such as spraying with insecticides and draining stagnating water in which they can breed [10, 11]. 
Despite a clear need, no vaccine offering a high level of protection currently exists, however, efforts to develop one are 
ongoing [12]. A number of medications (antimalarial drugs) are also available to prevent malaria (prophylaxis) while 
travelling to malaria endemic countries [13].  
Scientists do not yet totally understand the complex that promotes humans against malaria and so the search for a vaccine 
to eliminate the disease is considered to be one of the most important projects in public health [14]. With the drug 
resistance strains of Plasmodium, the use of anti-malaria drugs, singly has failed to curtail the prevalence of malaria, 
globally, particularly multi-drug resistance falciparum, so WHO has recommended that acute uncomplicated resistance 
falciparum malaria should be treated by combining one of the artemisinin compound with another effective erythrocytic 
schizontocide [15]. 
Dihydroartemisinin-piperaquine phosphate (DHAPP) is an artemisinin based combination therapy drug consisting of 
dihydroartemisinin (40mg) and piperaquine phosphate (320mg). Piperaquine is a bisquinoline, first synthesized in the 
sixties in China and France, which is as effective as chloroquine [3]. The tolerability, efficacy, pharmacokinetic profile 
and low cost of piperaquine make it a promising combination drug for an artemisinin combined based therapy (ACT). 
DHAPP, being an artemisinin based combined therapy is very effective in treating malaria in areas of high resistance to 
conventional anti-malaria drug. The drug is usually being prescribed as an alternative to other artemisinin combined 
therapy such as Coartem [5]. The artemisinin-derivatives (artemether, artesunate, and dihydroartemisinin) are currently 
the most potent anti-malarial medicines in the market [3]. They are widely available in the different pharmaceutical 
dosage forms including tablets, injections, suppositories and dry powders [16]. 
Dihydroartemisinin-piperaquine phosphate (DHAPP) is an affordable drug generally used by people in Nigeria for 
treatment of malaria [3]. Many people are still unaware of its efficacy as an antimalarial agent because it is not very 
popular. There is also paucity of information on the toxicological effects of the administration of the drug. 
The objective of the research work is to investigate the safety of the use of therapeutic dose of dihydroartemisinin-
piperaquine phosphate on biochemical parameters as well as toassess the histology of the kidney on the rats administered 
with dihydroartemisinin-piperaquine phosphate. This research work is of significance to malaria treatment as it assesses 
the toxicological effects of the use of therapeutic dose of dihydroartemisinin-piperaquine phosphate on adult male and 
female rats. 
2. Materials and Methods 
2.1 Chemicals and Reagents. The chemicals used include diethyl ether from May and Baker Ltd., Dagenham, 
England, phosphate buffer (Na2HPO4 and NaH2PO4) from Randox Laboratories Ltd. Crumlin, United Kingdom, sodium 
chloride (NaCl), ethylene diaminetetraacetic acid (EDTA) were purchased from BDH Chemical Limited, Poole, England. 
Distilled water was obtained from the laboratory of Biochemistry Department, Olabisi Onabanjo, University, Ikenne 
Remo Campus, Ikenne, Nigeria. All other chemicals used are of analytical grade.  
2.2 Animal Ethics. All procedures involving animals in this study conformed to the guiding principles for research 
involving animals as recommended by the Declaration of Helsinki and the Guiding Principles in the Use of Animals [17]. 
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2.3 Drugs, Animals and Diet. The dihydroartemisinin-piperaquine phosphate (DHAPP) tablet was obtained from 
Bliss GVS Pharma Limited, India. Thirty adult wistar strain rats of both sexes (15 male and 15 female), weighing 
between 180 and 210g were obtained from the Physiology Department, Olabisi Onabanjo University, Remo Campus, 
Ikenne, Ogun State. 
The rats were fed with standard rat pellets (Top Feed Nigeria Ltd., Ibadan, Nigeria) and water ad libitum and were 
housed in separate improvised cages under photo-period controlled environment (12 hours dark, 12 hours light cycles; 
24-25
o
C) at the animal house of Olabisi Onabanjo University, Biochemistry Department, Remo Campus, Ikenne, Ogun 
State. 
2.4 Experimental Design. The rats were divided into three groups consisting of five male and five female each which 
were housed separately in an improvised animal cages. Group I (Control Group) consists of five male and five female 
Wister rats which were fed with rat pellets and water ad-libitum throughout the study. They were orally administered 
with normal saline; Group II (Test Group) consists of five male and five female Wister rats were fed with rat pellets and 
water ad-libitum. They were orally administered with 15.4 mg/kg body weight of DHAPP for three days; and Group III 
(Recovery Group) consists of five male and five female Wister rats were fed with rat pellets and water ad-libitum. They 
were orally administered with 15.4mg/kg body weight of DHAPP for three days and were allowed to recover from the 
drug’s effect for another three days.  
2.5 Animal Sacrificing and Sample Collection. Twenty four (24) hours after the last administration for groups A 
and B and fourth day after recovery for group C, the animals were anaesthetized using diethyl ether. Using sterile 
forceps, the animals were dissected and blood collected through cardiac puncture using Norject syringe (10ml). The 
blood collected was immediately transferred to heparinised bottle to prevent clotting. The blood samples collected were 
centrifuged at 5000 rpm for 10 minutes to separate plasma and the packed cells. The plasma was kept in a clean specimen 
bottles placed in ice bucket and stored frozen until they were analyzed for the kidney function tests. 
The kidney were surgically removed, rinsed in ice cold 0.85% NaCl (normal saline), blotted dry and weighed. One gram 
of the liver were homogenized and centrifuged. The supernatant were kept in clean bottles and stored frozen at 4°C for 
assay. 
2.6 Biochemical and Histological Analyses. The protein concentration was determined by Biuret method [18], 
creatinine concentration was determined by the method of Jaffé [19] and urea concentration was determined by 
Berthelot’s reaction [19]. The histology of the kidney was studied as described by the method of Drury et al. [20]. 
2.7 Statistical Analysis. The data were analysed using SPSS version 17.0 and the values were expressed as mean ± 
SEM (Standard Error of Mean). The means of the groups were compared using one way ANOVA (Analysis of Variance) 
while the sex differences were compared using Primer of Biostatistics version 3.01 and level of significance was 
determined using Duncan Multiple Range Test (DMRT) at p<0.05. 
3. Results and Discussion 
3.1 Effect of Dihydroartemisinin-Piperaquine Phosphate (DHAPP) on Protein, Creatinine and Urea in 
the Plasma of Experimental and Control Rats. There was a significant increase in plasma protein (at p<0.05) in 
both sexes of the rats when the drug was administered but the level was reduced during recovery (Table 1). During the 
recovery process, the values were brought towards normal. Sex related difference was observed only in control group 
(Table 1) Also, there is a significant increase in the creatinine level in the plasma of both sexes when the drug was 
administered but was reduced during recovery (Table 1). Moreover, sex differences were observed in the male and 
female DHAPP treated group. The differences were higher in the male animals than in the females (Table 1). The result 
showed that there is significant increase in the urea level in the plasma of both male and female animals when the drug 
was administered which was reduced during recovery. There was also sex related differences in both treated and recovery 
groups (Table 1). 
The result (Table 2) of the treatment on the homogenate from the kidney shows a reduction in the kidney protein, 
creatinine and urea level of male and female animals. A significant difference was observed in protein level between the 
males and females animals in the control, when DHAPP was administered as well as when allowed to recover (Table 2). 
Sex related differences were also noted in the creatinine level of control animals and recovery group which was higher in 
male than in female. The result also shows that there was sex related differences in the control, DHAPP treated and 
recovery group in the kidney protein, creatinine and urea level of the animals. 
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Table 1. Effect of dihydroartemisinin-piperaquinephosphate (DHAPP) on protein, creatinine and urea 
in the plasma ofexperimental and control rats 
Values are expressed as Mean of 5 replicates ± SEM (Standard Error of Mean) and data were 
subjected to one way analysis of Variance (ANOVA) and level of significance were done using 
Duncan Multiple Range Test (DMRT) at P < 0.05 of SPSS version 17.0 software. Different 
superscripts along a column indicate significant difference (a<b<c). Sex differences were determined 
using Primer of Biostatistics version 3.01.Different superscriptsacrossthe row indicate significant 
difference (x<y). 
Table 2. Effect of dihydroartemisinin-piperaquinephosphate (DHAPP) on protein, creatinine 
and urea in the kidney of experimental and control rats 
 
 
Values are expressed as Mean of 5 replicates ± SEM (Standard Error of Mean) and data were subjected to one way 
analysis of Variance (ANOVA) and level of significance were done using Duncan Multiple Range Test (DMRT) at P < 
0.05 of SPSS version 17.0 software. Different superscripts along a column indicate significant difference (a<b<c). Sex 
differences were determined using Primer of Biostatistics version 3.01.Different superscriptsacrossthe row indicate 
significant difference (x<y). 
3.2Photomicrograph of the Kidney of Rats Treated with Dihydroartemisinin-Piperaquine Phosphate 
(DHAPP). Histopathological examination revealed that DHAPP may cause progressive and degenerative changes in the 
kidney. The pathological observation showed degenerative changes in the DHAPP treated group while the control groups 
appear normal. The recovery groups were also observed to return to normal after the withdrawal of the drug. 
Main function of the kidney is to excrete the waste products of metabolism and to regulate the body concentration of 
water and salt.  Plate 1 showed the photomicrographs of the kidney of control, test and recovery groups. Histological 
study of the normal kidney revealed normal glomerulus surrounded by the Bowman’s capsule, proximal and distal 
convoluted tubules without any inflammatory changes. The kidney of the tested rats group revealed renal tubular 
hypertrophy resulting in reduced luminal diameter especially in the male group. The recovery groups showed restoration 
to the normal renal structural arrangements with re-established tubular lumen.    
Group Protein (g/100ml) Creatinine (mg/dl) Urea (mg/dl) 
Male Female Male Female Male Female 
Control 3.66±0.11
ax
 4.54±0.17
ay
 0.12±0.01
ax
 0.11±0.01
ax
 22.04±0.10
cx
 21.34±0.34
ax
 
DHAPP treated 5.34±0.07
cx
 5.24±0.07
bx
 0.34±0.01
by
 0.18±0.03
bx
 29.14±0.10
ax
 30.79±0.25
cy
 
Recovery 4.58±0.09
bx
 4.74±0.23
ax
 0.14±0.02
ax
 0.09±0.01
ax
 26.37±0.18
by
 24.14±0.29
bx
 
Group Protein (g/100ml) Creatinine (mg/dl) Urea (mg/dl) 
Male Female Male Female Male Female 
Control 5.19±0.07
b
x
 
5.78±0.08
cy
 3.70±0.15
cy
 1.51±0.08
cx
 151.73±0.56
cx
 155.83±0.18
by
 
DHAPP treated 4.51±0.06
ay
 4.15±0.05
ax
 0.49±0.01
ay
 0.31±0.02
ax
 87.73±0.61
ax
 86.27±9.75
ax
 
Recovery 5.25±0.08
b
y
 
4.67±0.09
bx
 2.39±0.02
by
 0.51±0.01
bx
 96.11±0.13
by
 89.49±0.18
ax
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The above changes in treatment rats were observed to be prominent in the female group when compared to the male.  
 
 
 
 
PLATE 1.Showing photomicrographs of the kidney of control, test  & recovery groups:  a: Female Control, H&E, X100; 
b: Female Test, H&E, X100; c:Female  Recovery, H&E, X100; d: Male Control, H&E, X100; e: Male Test, H&E, X100; 
f:Male  Recovery, H&E, X100. Yellow arrow (renal tubule); Red arrow ( Renal corpuscle) 
A significant increase in the plasma protein, creatinine and urea level upon the administration of DHAPP was observed 
and this was reduced to normal when the animals were allowed to recover from the administration of the drug.It was 
revealed that the concentration of protein, creatinine and urea in the kidney significantly reduced when compared with 
their plasma concentration. 
a 
f c 
e b 
d 
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Creatinine and urea released is excreted from the blood by the kidneys when there is abnormality in the body system. 
Increased level of creatinine in the treated rats as revealed in the present study may be due to post renal obstruction [21]. 
Damage to the kidney will make the kidney inefficient to excrete both urea and creatinine and causes the accumulation in 
blood. Therefore, high level of plasma urea and creatinine will indicate kidney damage. The sex related differences 
observed could be attributed to physiological, hormonal and genetic differences between male and female animals [22]. 
The current investigations suggest intoxication of the kidney cells of the rats upon DHAPP administration as revealed by 
the biochemical and histological findings. The kidney cell damage may have been caused by highly reactive free radicals 
generated by DHAPP, which is also responsible for antimalarial actions as a result of the oxidative stress caused by 
DHAPP. The generation of ROS leads to accumulation of lipid peroxides leading to a change in permeability of the cells. 
The deleterious effects were considered to be caused by free radicals produced during peroxide formation. The findings 
in this study agree with the work of Olayinka and Ore [3] and Ngokere et al. [23] where DHAPP and artesunate were 
observed to cause degenerative changes in the kidney. 
4. Conclusion 
Dihydroartemisinin-Piperaquine Phosphate (DHAPP) as a form ofartemisinin has been considered to have high safety 
margin, however, the results of this study confirmed that the administration of therapeutic dose of DHAPP may not be 
anaemic but may inducemarked renal and hepatic damages.  
It is recommended that care should be taken in administering Dihydroartemisinin-Piperaquine Phosphate (DHAPP). 
Lower concentration of the drug with an increase in the number of days required for the use of the drug should also be 
considered.It is also recommended that further research work should be done to study the haematological, hepatotoxicity 
and nephrotoxicity of the drug in malarial infected animal model and patients. 
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